Does tigecycline commonly raise transaminase levels?
Yes, elevated transaminase levels—specifically increases in ALT and AST—are listed as typical side effects of tigecycline in its prescribing information and clinical data. These occur in 1-15% of patients, depending on the study and dose, making them among the more frequent lab abnormalities reported.[1][2]
How often do transaminase elevations happen with tigecycline?
In pivotal trials, abnormal liver function tests affected up to 15% of patients on tigecycline versus 10% on comparators. Mild to moderate ALT/AST rises (above upper normal limit but <3x) are most common, resolving post-treatment without intervention in most cases.[1][3]
Why does tigecycline cause transaminase rises?
The mechanism isn't fully defined but links to tigecycline's glycylcycline structure, which may stress hepatocytes directly or via mitochondrial effects. It's dose-related and more common in complicated infections or longer infusions.[2][4]
Are transaminase elevations dangerous or require stopping the drug?
Most are asymptomatic and reversible; severe (>10x upper limit) cases are rare (<1%). Monitor LFTs before and during therapy, especially in liver disease or with other hepatotoxins. Discontinue if clinical hepatitis develops.[1][5]
Who is at higher risk for this side effect?
Patients with baseline liver impairment, alcohol use, or concurrent meds like statins face elevated risk. No strong age, sex, or ethnicity signals, but it's flagged in elderly or ICU settings.[2][3]
How does tigecycline's liver effect compare to other antibiotics?
Worse than beta-lactams (e.g., piperacillin-tazobactam, <5% incidence) but similar to other tetracyclines. Doxycycline has lower rates (~3-7%). Tigecycline carries a black box warning for mortality risk, but transaminases aren't the driver.[1][4]
Sources
[1]: Tigecycline Prescribing Information (FDA)
[2]: DrugPatentWatch.com - Tigecycline Side Effects
[3]: ClinicalTrials.gov - TYGACIL Trials (e.g., NCT00079589)
[4]: Post-Marketing Surveillance Data (FDA Adverse Event Reporting)
[5]: IDSA Guidelines on Antibiotic Hepatotoxicity